Nutr Metab (Lond). 2021 Mar 10;18(1):26. doi: 10.1186/s12986-021-00553-4.
Integrative proteomic and lipidomic analysis of Kaili Sour Soup-mediated attenuation of high-fat diet-induced nonalcoholic fatty liver disease in a rat model.
Nutrition & metabolism
Shuo Cong, Zhengchao Li, Lei Yu, Yongmei Liu, Yaxin Hu, Ying Bi, Mingliang Cheng
Affiliations
Affiliations
- School of Basic Medicine Sciences, Guizhou Medical University, Guiyang City, China.
- Guizhou Cancer Hospital, Guiyang City, China.
- Graduate School of Guizhou Medical University, Guiyang City, China.
- Maternal and Child Health Hospital of Guiyang City, Guiyang City, China.
- Department of Infectious Diseases, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang City, 550004, Guizhou Province, China.
- Department of Infectious Diseases, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang City, 550004, Guizhou Province, China. [email protected].
PMID: 33691721
PMCID: PMC7945315 DOI: 10.1186/s12986-021-00553-4
Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease and is characterized by excessive fat accumulation. Kaili Sour Soup, a food typical of Guizhou Province, is believed to have significant health benefits. Thus, we aimed to identify and assess the impact of Kaili Sour Soup on NAFLD and its underlying mechanism using integrative proteomic and lipidomic analysis.
METHODS: A high-fat diet and male Wistar rats were used to construct a NAFLD rat model. Haematoxylin and eosin (HE) and Oil Red O staining analyses were used to perform the histologic examination. Proteomic analysis was utilized to systematically identify the global protein profile in NAFLD with and without Kaili Sour Soup treatment. Western blot assays were used to verify the expression of proteins screened by proteomic analysis. Lipidomic analysis was performed to screen lipid metabolism in NAFLD with and without Kaili Sour Soup treatment.
RESULTS: Kaili Sour Soup alleviated high-fat diet (HFD)-induced fatty liver and had a normalizing effect on physiological and biochemical indicators of NAFLD, including body weight, liver weight, liver index, total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and insulin resistance level of homeostasis model assessment (HOMA-IR). Kaili Sour Soup decreased the levels of 13 proteins (Tmem44, Rnaseh2b, Gstm6l, LOC100910877, Rufy4, Slc12a2, Pcif1, P4503A1, Sult1e1, Nop53, AABR07065656.4, AABR07065789.3) that were upregulated by HFD and increased the levels of 3 proteins (Sult1c2, Sult1c2a, Snrnp48) that were downregulated by HFD. Kaili Sour Soup attenuated the HFD-induced increase in acyl carnitine (AcCa) and enhanced the HFD-induced decreases in gangliosides (GM3) and lysophosphatidylserine (LPS) in the NAFLD rat model.
CONCLUSIONS: Altogether, this study revealed that Kaili Sour Soup attenuated HFD-induced fatty liver and systematically identified abnormal proteins and lipids involved in the role of Kaili Sour Soup in a NAFLD rat model.
Keywords: Kaili Sour Soup; Lipidomics; Nonalcoholic fatty liver disease; Proteomics
References
- Mol Metab. 2014 May 20;3(5):565-80 - PubMed
- Hepatology. 2019 Oct;70(4):1457-1469 - PubMed
- Curr Opin Clin Nutr Metab Care. 2017 Mar;20(2):110-116 - PubMed
- J Clin Invest. 2010 Oct;120(10):3713-21 - PubMed
- Nutrients. 2017 Sep 06;9(9): - PubMed
- J Biol Chem. 2008 Nov 28;283(48):33736-49 - PubMed
- ACS Omega. 2020 Apr 29;5(20):11314-11323 - PubMed
- Nature. 2014 May 15;509(7500):282-3 - PubMed
- J Endocrinol. 2012 Oct;215(1):59-70 - PubMed
- Ann Intern Med. 1997 Jan 15;126(2):137-45 - PubMed
- PLoS One. 2017 Feb 17;12(2):e0172348 - PubMed
- Curr Pharm Biotechnol. 2012 Apr;13(5):726-35 - PubMed
- Antioxid Redox Signal. 2012 Dec 1;17(11):1580-9 - PubMed
- Environ Toxicol Pharmacol. 2016 Jul;45:52-62 - PubMed
- Eur J Biochem. 1992 Jan 15;203(1-2):107-13 - PubMed
- Xenobiotica. 2011 Jun;41(6):494-500 - PubMed
- Metabolism. 2018 Jun;83:1-10 - PubMed
- J Lipid Res. 1978 Jul;19(5):538-43 - PubMed
- Diabetes. 2013 Jan;62(1):1-8 - PubMed
- Can J Gastroenterol Hepatol. 2014 Dec;28(11):607-18 - PubMed
- Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):125-35 - PubMed
- J Clin Invest. 1994 May;93(5):2007-13 - PubMed
- PLoS One. 2017 Aug 10;12(8):e0181052 - PubMed
- Cell Mol Life Sci. 2018 Sep;75(18):3313-3327 - PubMed
- J Endocrinol. 2015 Dec;227(3):153-65 - PubMed
- BMC Bioinformatics. 2014;15 Suppl 7:S9 - PubMed
- Xenobiotica. 2009 Dec;39(12):889-902 - PubMed
- Nat Methods. 2009 May;6(5):359-62 - PubMed
- Free Radic Biol Med. 2019 Nov 20;144:293-309 - PubMed
- J Womens Health (Larchmt). 2015 Dec;24(12):969-71 - PubMed
- Front Cell Dev Biol. 2019 Oct 25;7:248 - PubMed
- J Lipid Res. 2015 Mar;56(3):722-36 - PubMed
Publication Types
Grant support